Surprising
In 163 obese adults with sleep apnea, adding vitamin D3 to a diabetes drug improved metabolic markers — but only in an open-label trial that compared combo therapy to either treatment alone.
This is the first study to test this specific drug-and-supplement pairing, and while the combination outperformed solo treatments, the lack of blinding and small, narrow population mean the result is intriguing but far from settled.
Researchers gave 163 hypertensive, obese adults with sleep apnea either vitamin D3, the SGLT2 inhibitor dapagliflozin, both together, or nothing for 16 weeks. The combo group saw better metabolic numbers and nighttime heart rates than any other group. However, the same study found no effect on uric acid or HbA1c, and because neither patients nor doctors knew who got what, the surprise benefit needs confirmation before anyone changes their routine.
Where this fits in the evidence
This is among the first studies we've indexed on Vitamin D for Improved Metabolic Parameters — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- n = 163
- 2025-03-07
- Journal of translational medicine
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.